Journal of Surgical Oncology最新文献

{"title":"Cancer-Specific Survival of Trimodal Therapy Versus Radical Cystectomy in T2N0M0 Non-Urothelial Bladder Cancer.","authors":"Mattia Longoni, Andrea Marmiroli, Fabian Falkenbach, Quynh Chi Le, Michele Nicolazzini, Calogero Catanzaro, Federico Polverino, Jordan A Goyal, Matteo Ferro, Markus Graefen, Felix K H Chun, Carlotta Palumbo, Riccardo Schiavina, Nicola Longo, Fred Saad, Shahrokh F Shariat, Marco Moschini, Giorgio Gandaglia, Francesco Montorsi, Alberto Briganti, Pierre I Karakiewicz","doi":"10.1002/jso.70014","DOIUrl":"https://doi.org/10.1002/jso.70014","url":null,"abstract":"<p><strong>Introduction: </strong>We hypothesized that, within organ-confined (OC, T2N0M0) non-urothelial carcinoma of urinary bladder (non-UCUB) patients, trimodal therapy (TMT) use does not differ from radical cystectomy (RC) regarding cancer control outcomes.</p><p><strong>Methods: </strong>Within the SEER database (2004-2021), rates of TMT versus RC use in OC non-UCUB patients were calculated. Nearest-neighbor 1:1 propensity score matching (PSM) for age, sex, race/ethnicity, and histological subtype was applied. Cumulative incidence plots depicted 5-year cancer-specific (CSM) and other-cause mortality (OCM) rates. Multivariable competing risks regression (CRR) models were fitted. Sensitivity analyses were performed within squamous cell (SCC), neuroendocrine (NEC), and adenocarcinoma (ADK) and other histological subtypes.</p><p><strong>Results: </strong>Of 814 OC non-UCUB patients, 310 (38%) received TMT versus 504 (62%) RC. After PSM, 5-year CSM rate was 50% after TMT versus 29% after RC and TMT was associated with 2.1-fold higher CSM relative to RC (multivariable HR [mHR]: 2.1, p < 0.001). In sensitivity analyses within 229 (28%) SCC, TMT patients had higher 5-year CSM rates relative to their RC-counterparts (67% vs. 22%, mHR: 4.3, p < 0.001). Similarly, within 314 (39%) NEC, TMT patients had higher 5-year CSM rates relative to their RC-counterparts (mHR: 1.8, p < 0.001). Conversely, within 118 (28%) ADK and 153 (19%) other subtypes, CSM after TMT did not differ from CSM after RC (33% vs. 15%, mHR: 1.4 and 43% vs. 33%, mHR: 1.4; p = 0.4).</p><p><strong>Conclusion: </strong>In OC non-UCUB patients TMT is associated with significantly higher CSM than RC. Most pronounced survival disadvantage was recorded within SCC and NEC patients.</p>","PeriodicalId":17111,"journal":{"name":"Journal of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144285078","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of Machine Learning Models to Predict Tumor Endoprosthesis Survival.","authors":"Barlas Goker, Andrew Brook, Ranxin Zhang, Boudewijn Aasman, Jichuan Wang, Alexander Ferrena, Parsa Mirhaji, Rui Yang, Bang H Hoang, David S Geller","doi":"10.1002/jso.70001","DOIUrl":"https://doi.org/10.1002/jso.70001","url":null,"abstract":"<p><strong>Background and objectives: </strong>Endoprosthetic reconstruction is the preferred approach for limb salvage surgery for many patients following malignant bone tumor resection. Implant failure is a common complication, however, there are no reliable means with which to offer patient-specific survival estimations. Implant survival predictions can set patient expectations and may guide treatment planning. This study aims to test and compare machine-learning models for the prediction of early tumor endoprosthetic implant survival.</p><p><strong>Methods: </strong>A single-center retrospective series of 138 cases (mean age 41, 70 males, 68 females) was split into an 80:20 training and testing set. XGBoost, random forest, decision tree learning, and logistic regression were trained and assessed for model performance. After an initial review, age, sex, body mass index, diagnosis, location, resection length, and number of surgeries were selected as features. The output variables were 12-month, 24-month, and 36-month implant survival.</p><p><strong>Results: </strong>Random forest had the best performance at 12, 24, and 36 months with an area under the curve (AUC) of 0.96, 0.89, 0.88; accuracy of 0.92, 0.83, 0.75; and Brier score of 0.09, 0.11, 0.20, respectively. Overall, the models performed better at 12 months compared to the other time points. The most important feature at 12 months was resection length (0.17), whereas age was most important at 24 months (0.15) and 36 months (0.17). Online tools were created based on the random forest models.</p><p><strong>Conclusions: </strong>Machine learning models can be leveraged for the accurate prediction of early tumor endoprosthetic survival. These represent the first ML models used to predict endoprosthetic implant survival beyond 1 year and the first to include upper extremity implants. This offers better patient-specific prognostication which can help manage patient expectations and may guide recommendations.</p><p><strong>Level of evidence: </strong>Level III.</p>","PeriodicalId":17111,"journal":{"name":"Journal of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144275194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment On: \"Anemia, Abnormal Body Mass Index, and Sarcopenia Increase Complication Risk in Patients Undergoing Surgical Treatment for Metastatic Bone Disease\".","authors":"Erkan Topkan","doi":"10.1002/jso.70009","DOIUrl":"https://doi.org/10.1002/jso.70009","url":null,"abstract":"","PeriodicalId":17111,"journal":{"name":"Journal of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144266484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment On: \"Neoadjuvant Chemotherapy Is Associated With Reduced Amputation Risk in Synovial Sarcoma of the Lower Extremity\".","authors":"Mahdi Maloomi, Nima Masoudi","doi":"10.1002/jso.28165","DOIUrl":"https://doi.org/10.1002/jso.28165","url":null,"abstract":"","PeriodicalId":17111,"journal":{"name":"Journal of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144266485","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Soluble sFas, sFasL, sPD1, and sPDL1 Analyses in the Peripheral Blood of Locally Advanced Breast Cancer Patients Before and After Neoadjuvant Chemotherapy.","authors":"Carolina de Souza Vasconcelos, Marcelo Ramos Tejo Salgado, Mario Rino Martins, Carlos Eduardo Caiado Anunciação, Denise Viana Sobral, Leuridan Cavalcante Torres","doi":"10.1002/jso.27723","DOIUrl":"https://doi.org/10.1002/jso.27723","url":null,"abstract":"<p><strong>Background: </strong>Neoadjuvant chemotherapy (NAC) is currently widely indicated for treatment of breast cancer (BC), due to several advantages that include early introduction of systemic therapy, determine drug's efficacy, potential to reduce both the tumor volume of the primary tumor and regional lymph nodes, reduction in the extent of surgery in the breast and axilla, evaluation of the pathological response, and rescue therapies in specific cases. Several studies have demonstrated better long-term outcomes among patients who achieve pathologic complete response (pCR) than those with residual tumor (non-pCR). The association between pCR and long-term outcomes is strongest among HER2+ and triple-negative breast cancer (TNBC). Therefore, evaluating the efficacy of chemotherapy in real time is an important issue.</p><p><strong>Methods: </strong>Between 2016 and 2018, a cohort carried out of 37 patients with locally advanced BC: 21 women with TNBC and 16 HER2+ submitted to NAC.</p><p><strong>Results: </strong>High levels of sPD1 and sFas in the plasma of TNBC and HER2 patients compared to the controls (p < 0.05). Low levels of sPDL1 in HER2+ patients with pCR compared to non-pCR (p = 0.021). In paired analysis, statistical differences of sFasL levels in TNBC and HER2+ patients before and after NAC (p = 0.0065 and p = 0.041, respectively), and in sFAS levels in HER2+ patients before and after NAC (p = 0.0071).</p><p><strong>Conclusion: </strong>The present study suggests that soluble sFas, sFasL, sPD1, and sPDL1 levels were apoptosis-related markers with potential predictive value of response to neoadjuvant chemotherapy in patients with TNBC and HER2+ breast cancer.</p>","PeriodicalId":17111,"journal":{"name":"Journal of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144208769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Burden of Colorectal Cancer Treatment on Quality of Life: A Paired Longitudinal Analysis of Medicare Advantage Enrollees.","authors":"Emna Bakillah, J Walker Rosenthal, Solomiya Syvyk, Chris Wirtalla, James Sharpe, Raina M Merchant, Shivan J Mehta, Carmen E Guerra, Rachel R Kelz","doi":"10.1002/jso.28161","DOIUrl":"https://doi.org/10.1002/jso.28161","url":null,"abstract":"<p><strong>Background and objectives: </strong>Treatment of colorectal cancer (CRC) can have prolonged effects on health-related quality of life (HRQOL). Using the Medicare Health Outcomes Survey (MHOS), this study examines HRQOL outcomes among those undergoing CRC treatment and those who completed CRC treatment.</p><p><strong>Methods: </strong>We performed a paired longitudinal retrospective cohort study of Medicare Advantage enrollees ≥ 65 years of age who completed the baseline and follow-up MHOS from 2016 to 2020 and answered survey questions regarding current CRC treatment. Outcomes included Physical Component Summary (PCS) scores and Mental Component Summary (MCS) scores. Multivariable logistic regression analyses were used.</p><p><strong>Results: </strong>574 Respondents met the inclusion criteria. Those currently undergoing treatment for CRC had significantly lower PCS scores (β coefficient -3.08 points, p < 0.001) and significantly lower MCS scores (β coefficient -1.40 points, p = 0.008) at follow-up compared to when they were not undergoing CRC treatment at baseline. Respondents who completed CRC treatment had PCS and MCS scores that remained similar over time (β coefficient 0.54 points, p = 0.466 and 0.07 points, p = 0.924, respectively).</p><p><strong>Discussion: </strong>Treatment of CRC negatively influences HRQOL. These findings emphasize the importance of informing patients of the long-term effects of CRC treatment and support the implementation of interventions aimed at providing sustained recovery throughout the survivorship continuum.</p>","PeriodicalId":17111,"journal":{"name":"Journal of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144199457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Methodological and Survival Comparison of NCDB and SEER Database for Colon Cancer Research.","authors":"Metincan Erkaya, Ekin Inal, Cigdem Benlice, Mehmet Ayhan Kuzu, Emre Gorgun","doi":"10.1002/jso.28141","DOIUrl":"https://doi.org/10.1002/jso.28141","url":null,"abstract":"<p><strong>Background: </strong>The National Cancer Database (NCDB) and Surveillance, Epidemiology, and End Results (SEER) database are widely used in colon cancer research, particularly for analyzing overall survival (OS) rates. However, differences in demographics, treatment patterns, and survival outcomes across colon cancer stages and locations between these databases remain incompletely understood. Addressing these disparities is crucial for researchers when selecting the most appropriate registry for survival analysis.</p><p><strong>Objectives: </strong>This study aims to systematically compare patient characteristics, oncologic outcomes, and OS rates between NCDB and SEER across various tumor locations and disease stages in colon cancer.</p><p><strong>Methods: </strong>We analyzed patients undergoing surgery for Stages I-IV primary colon cancer (2004-2019), comparing patient characteristics, oncologic outcomes, and OS rates across distinct tumor locations and cancer stages in NCDB and SEER. Our objective was to assess how differences in database structure and sampling methodologies influence reported survival outcomes.</p><p><strong>Results: </strong>The study included 777 827 patients (NCDB: 572 196; SEER: 205 631). Proximal colon cancers were more common in older and female patients in both databases, whereas distal colon cancers were more prevalent in younger patients. NCDB contained a slightly higher proportion of Caucasian patients, while SEER had a greater representation of Asian patients. Segmental resections were more frequent in SEER, with the highest weighted difference observed in sigmoid colon cancer (6.16%; 95% CI: 5.78%-6.54%). OS rates were generally comparable across databases, though minor variations were observed at different colonic locations and stages.</p><p><strong>Conclusion: </strong>Despite differences in sampling techniques and follow-up reporting, NCDB and SEER demonstrated remarkable consistency in survival trends across colon cancer stages and locations. Recognizing these database-specific variations is essential for researchers conducting population-based survival analyses and selecting the most suitable registry for their studies. WHAT DOES THIS PAPER ADD TO THE LITERATURE?: This study provides a comprehensive comparison of NCDB and SEER, highlighting how differences in sampling methodologies, follow-up reporting, and patient representation influence overall survival estimates in colon cancer. It clarifies why prior studies report conflicting survival trends and offers a methodological framework for researchers selecting the most appropriate database for their analysis.</p>","PeriodicalId":17111,"journal":{"name":"Journal of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144182212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preoperative Anemia and Iron Deficiency in Elective Gastrointestinal Cancer Surgery Patients.","authors":"Yiwen Chen, Jie Zhou, Mengjiao Hu, Fangfang Tao","doi":"10.1002/jso.28164","DOIUrl":"https://doi.org/10.1002/jso.28164","url":null,"abstract":"","PeriodicalId":17111,"journal":{"name":"Journal of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144150842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to Comment on \"Development and Validation of a Predictive Score for Preoperative Detection of Lymphovascular Invasion in Rectal Cancer\".","authors":"Sameh Hany Emile, Steven D Wexner","doi":"10.1002/jso.28133","DOIUrl":"https://doi.org/10.1002/jso.28133","url":null,"abstract":"","PeriodicalId":17111,"journal":{"name":"Journal of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144150843","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Brazilian Society of Surgical Oncology (SBCO) Guidelines for the Treatment of Exocrine Pancreatic Insufficiency in Cancer Patients.","authors":"Rodrigo Nascimento Pinheiro, Anelisa Kruschewsky Coutinho, Pedro Eder Portari Filho, Felipe Henning Gaia Duarte, Marcos Gonçalves Adriano Junior, Guilherme de Andrade Gagheggi Ravanini, Felipe José Fernández Coimbra, Flavio Daniel Saavedra Tomasich, Fernando Ernesto Cruz Felippe, Rafael Oliveira Albagli, Alexandre Menezes de Brito, Heládio Feitosa E Castro Neto, Alexandre Ferreira Oliveira","doi":"10.1002/jso.28162","DOIUrl":"https://doi.org/10.1002/jso.28162","url":null,"abstract":"<p><p>Exocrine pancreatic insufficiency (EPI) in oncology patients requires careful attention due to its clinical significance and frequent underdiagnosis. This narrative review and Guideline established by the Brazilian Society of Surgical Oncology suggest a practical approach to diagnosis and pancreatic enzyme replacement therapy (PERT). This promising approach can improve symptoms, nutritional status, and quality of life, potentially positively impacting survival in unresectable pancreatic cancer and postsurgical settings.</p>","PeriodicalId":17111,"journal":{"name":"Journal of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144142859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}